MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ONCO Stock slipped -1.99% Today — RQD Quant Desk Flash
$0.59 -1.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.59
Onconetix Inc. (ONCO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $3.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.59 (-0.55%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ONCO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY ONCO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (33% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.62-22.6% Next Q
44
Q2 (-2Q)Grade D$0.48-12.5% Next Q
41
Q3 (-1Q)Grade E$0.42+40.5% Next Q
39
CurrentGrade D-$0.59-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ONCO Turnaround Squeeze
While ONCO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.62) forces dealer call-delta covering toward $174.56.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ONCO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ONCO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ONCO Stock slipped -1.99% Today — RQD Quant Desk Flash
Onconetix Inc. (ONCO) slipped -1.99% to $0.59, trading at 2% of its 52-week range ($0.34 – $166.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.34 – $166.25) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 63.3% gross margin and $0 annual free cash flow.
Live ONCO Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ONCO)
- ✓Walkthrough of ONCO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ONCO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.51%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.54H $0.59L $0.52C $0.59VOL 1.17M
RES: $1.52SUP: $0.32SMA50: $0.66SMA200: $13.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ONCO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ONCO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ONCO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ONCO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ONCO)
Health Care Rank #803 of 1016
⚔️ ERNA vs ONCO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ONCO vs. ERNA, GRI, CVKD, EOCN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Onconetix Inc. (ONCO) ranks #803 by composite RQD confidence (36/100, grade D-) and #971 by equity capitalization ($3.5M). Within this direct 5-issuer industry benchmark cohort, ONCO leads on earnings valuation at N/A trailing P/E, while ONCO leads on capital efficiency and profitability with -35.0% ROIC and 77.6% gross margin. EOCN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ONCO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ONCO
ACTIVE
Onconetix Inc. | D- | 36/100 | — | 77.6% | -35.0% | -1.99% | $3.5M | Benchmark Subject |
| ERNA Ernexa Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +6.57% | $3.4M | /erna-vs-onco → |
| GRI GRI Bio Inc. | D- | 38/100 | — | — | -35.0% | -3.38% | $3.4M | /gri-vs-onco → |
| CVKD Cadrenal Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -0.47% | $3.4M | /cvkd-vs-onco → |
| EOCN Eocene Ltd. | D | 47/100 | — | — | -35.0% | +0.62% | $3.4M | /eocn-vs-onco → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782107In its most recent audited fiscal period (FY2025, filed 2025-12-31), Onconetix Inc. (ONCO) reported GAAP revenue of $815.4K (-67.7% vs. FY2024 revenue of $2.5M , and +1294.6% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$9.7M, and free cash flow of -$9.7M (+8.0% YoY). On the balance sheet, ONCO closed FY2025 with $24.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $815.4K | -$14.0M | -$9.7M | -$9.7M | $24.9M | — |
| FY2024 (FY) | 2024-12-31 | $2.5M | -$58.7M | -$10.5M | -$10.5M | $28.2M | — |
| FY2023 (FY) | 2023-12-31 | $58.5K | -$37.4M | -$13.6M | -$13.6M | — | — |
3. ONCO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ONCO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Onconetix Inc. (NASDAQ: ONCO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.59 (-1.99% 1D, market cap $3.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ONCO ranks #803 in composite RQD confidence.
How does ONCO compare to ERNA and GRI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ONCO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 77.6%, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and GRI (GRI Bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M). Among the 5-stock peer group, ONCO leads on earnings multiple (N/A) while ONCO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ONCO?
Per ONCO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782107), Onconetix Inc. generated $815.4K in revenue (-67.7% YoY), -$14.0M in net income, and -$9.7M in free cash flow against $24.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ONCO trading relative to its 50-day, 200-day, and 52-week technical levels?
ONCO last traded at $0.59 (-1.99% on volume of 6,910,992 shares), positioning the stock -10.61% below its 50-day simple moving average ($0.66) and -95.75% below its 200-day simple moving average ($13.89). Across its 52-week range of $0.34 to $166.25, ONCO sits at the 0.2% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.66).
ONCO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ONCO stock moving today?
Why ONCO Stock slipped -1.99% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.